Gender difference in the pathophysiology and treatment of glaucoma

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Glaucoma is the principal cause of irreversible blindness in the world, the second leading cause of blindness in the United States, and it results in optic nerve head axonal degeneration and corresponding visual field deficits. Intraocular pressure (IOP) is the only known modifiable risk factor in glaucoma. Non-modifiable risk factors for glaucoma include age, ethnicity, central corneal thickness, and family history. While our understanding of the role of gender as a risk factor in glaucoma development and progression remains nascent, multiple observations have shown gender differences in the incidence and prevalence of glaucoma. Depending on the type of glaucoma, hormone therapy, oral contraceptive use and menopausal status have also been associated with glaucoma. In addition, pregnancy leads to changes in IOP, while the treatment of glaucoma must be tailored based on the systemic effects of topical therapeutics on the mother and fetus. This review will focus on the epidemiologic, anatomic and endocrinologic differences in male and female glaucoma patients. In addition, this review will discuss treatment modalities that may be more appropriate for one gender than the other, especially with respect to a woman's pregnancy status.

Original languageEnglish (US)
Pages (from-to)191-200
Number of pages10
JournalCurrent Eye Research
Volume40
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Glaucoma
Therapeutics
Blindness
Intraocular Pressure
Pregnancy
Women's Rights
Optic Disk
Therapeutic Uses
Oral Contraceptives
Visual Fields
Fetus
Mothers
Hormones
Incidence

Keywords

  • Gender
  • Glaucoma
  • Hormone therapy
  • Intraocular pressure
  • Pregnancy

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems
  • Cellular and Molecular Neuroscience

Cite this

Gender difference in the pathophysiology and treatment of glaucoma. / Tehrani, Shandiz.

In: Current Eye Research, Vol. 40, No. 2, 01.02.2015, p. 191-200.

Research output: Contribution to journalArticle

@article{a3a03fccb5fe4b37bfe2f9ab67681193,
title = "Gender difference in the pathophysiology and treatment of glaucoma",
abstract = "Glaucoma is the principal cause of irreversible blindness in the world, the second leading cause of blindness in the United States, and it results in optic nerve head axonal degeneration and corresponding visual field deficits. Intraocular pressure (IOP) is the only known modifiable risk factor in glaucoma. Non-modifiable risk factors for glaucoma include age, ethnicity, central corneal thickness, and family history. While our understanding of the role of gender as a risk factor in glaucoma development and progression remains nascent, multiple observations have shown gender differences in the incidence and prevalence of glaucoma. Depending on the type of glaucoma, hormone therapy, oral contraceptive use and menopausal status have also been associated with glaucoma. In addition, pregnancy leads to changes in IOP, while the treatment of glaucoma must be tailored based on the systemic effects of topical therapeutics on the mother and fetus. This review will focus on the epidemiologic, anatomic and endocrinologic differences in male and female glaucoma patients. In addition, this review will discuss treatment modalities that may be more appropriate for one gender than the other, especially with respect to a woman's pregnancy status.",
keywords = "Gender, Glaucoma, Hormone therapy, Intraocular pressure, Pregnancy",
author = "Shandiz Tehrani",
year = "2015",
month = "2",
day = "1",
doi = "10.3109/02713683.2014.968935",
language = "English (US)",
volume = "40",
pages = "191--200",
journal = "Current Eye Research",
issn = "0271-3683",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Gender difference in the pathophysiology and treatment of glaucoma

AU - Tehrani, Shandiz

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Glaucoma is the principal cause of irreversible blindness in the world, the second leading cause of blindness in the United States, and it results in optic nerve head axonal degeneration and corresponding visual field deficits. Intraocular pressure (IOP) is the only known modifiable risk factor in glaucoma. Non-modifiable risk factors for glaucoma include age, ethnicity, central corneal thickness, and family history. While our understanding of the role of gender as a risk factor in glaucoma development and progression remains nascent, multiple observations have shown gender differences in the incidence and prevalence of glaucoma. Depending on the type of glaucoma, hormone therapy, oral contraceptive use and menopausal status have also been associated with glaucoma. In addition, pregnancy leads to changes in IOP, while the treatment of glaucoma must be tailored based on the systemic effects of topical therapeutics on the mother and fetus. This review will focus on the epidemiologic, anatomic and endocrinologic differences in male and female glaucoma patients. In addition, this review will discuss treatment modalities that may be more appropriate for one gender than the other, especially with respect to a woman's pregnancy status.

AB - Glaucoma is the principal cause of irreversible blindness in the world, the second leading cause of blindness in the United States, and it results in optic nerve head axonal degeneration and corresponding visual field deficits. Intraocular pressure (IOP) is the only known modifiable risk factor in glaucoma. Non-modifiable risk factors for glaucoma include age, ethnicity, central corneal thickness, and family history. While our understanding of the role of gender as a risk factor in glaucoma development and progression remains nascent, multiple observations have shown gender differences in the incidence and prevalence of glaucoma. Depending on the type of glaucoma, hormone therapy, oral contraceptive use and menopausal status have also been associated with glaucoma. In addition, pregnancy leads to changes in IOP, while the treatment of glaucoma must be tailored based on the systemic effects of topical therapeutics on the mother and fetus. This review will focus on the epidemiologic, anatomic and endocrinologic differences in male and female glaucoma patients. In addition, this review will discuss treatment modalities that may be more appropriate for one gender than the other, especially with respect to a woman's pregnancy status.

KW - Gender

KW - Glaucoma

KW - Hormone therapy

KW - Intraocular pressure

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=84921667372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921667372&partnerID=8YFLogxK

U2 - 10.3109/02713683.2014.968935

DO - 10.3109/02713683.2014.968935

M3 - Article

VL - 40

SP - 191

EP - 200

JO - Current Eye Research

JF - Current Eye Research

SN - 0271-3683

IS - 2

ER -